ejpmr, 2021, 8(4), 723-728

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

DRUG-RESISTANT TUBERCULOSIS

Shruti Rajeev Gautam[1]* and Dr. Dhriti Rajeev Gautam[2]

[1]Department of Pharmacology, Vidya Bharati College of Pharmacy, C. K. Naydu Road, Camp Rd, Amravati, Maharashtra 444602.

[2]V.Y.W.S. Dental College & Hospital, Tapovan-Wadali Road, Amravati Camp, 444602.

***Corresponding Author: Shruti Rajeev Gautam**

Department of Pharmacology, Vidya Bharati College of Pharmacy, C. K. Naydu Road, Camp Rd, Amravati, Maharashtra 444602.

Article Received on 18/02/2021 **Article Revised on 10/03/2021** **Article Accepted on 31/03/2021**

ABSTRACT

Tuberculosis (TB) may be a global infectious threat that's intense by associate degree increasing incidence of extremely drug-resistant disease. A complete of 1.5 million folks died from TB in 2018 occurred worldwide; 3.3% of those cases resulted from multidrug-resistant infectious disease (MDR-TB) and extensively drug-resistant infectious disease (XDR-TB) strains. Prevalence of multidrug-resistant TB (MDR TB) cases is on the rise in India, and proportions of new cases of MDR. Treatment of drug-susceptible TB conducted under strong national TB programs (NTPs) using standard four-drug therapy and directly observed therapy (DOT) has led to relapse-free cure rates over 95% and dramatic national declines in TB incidence. The current proposal of DOTS and by the World Health Organization highlights the great management strategy to manage MDR-TB. MDR-TB may be an unreal downside and its emergence may be prevented by prompt designation and effective treatment of all TB cases along with the recent emergence of covid-19 that may reverse the latest progress in reducing the worldwide load of TB.

KEYWORDS: TB, HIV/TB, COVID-19 pandemic, Drug-resistant TB, management of DRTB.

INTRODUCTION

Tuberculosis (TB) is one of the eldest ailments of humankind and has co-developed with people for a huge number of years or maybe for a few million years. The oldest known molecular evidence of TB was detected in a fossil of an extinct bison (Pleistocene bison), which was radiocarbon dated at 17,870±230 years; and in 9000, year-old human remains which were recovered from a neolithic settlement in the Eastern Mediterranean.[1] the first of this genus to be identified was the lepra bacillus discovered by Hansen in 1868. Koch (1882) isolate the mammalian tubercle bacillus and provide its causative role in tuberculosis by satisfying Koch postulate. tuberculosis in a human was subsequently shown to be caused by two types of bacillus the human and bovine type designated mycobacterium tuberculosis and M.bovin. the term M. tuberculosis complex includes beside the human and bovine type, two other mammalian types also: M. africanum causing human tuberculosis in tropical Africa and possessing properties intermediate between human and bovine type and M. microti[2] M. microti isn't known to cause TB in humans; infection with M. africanum is very rare, while M. bovis features a wider host range and is that the main explanation for tuberculosis in other animal species. Humans become infected by M. Bovis, usually via milk, milk products or meat from an infected animal it's estimated that within the pre-antibiotic era, M. bovis was liable for about 6% of tuberculosis deaths in humans. Despite newer modalities for diagnosis and treatment of TB, unfortunately, millions of people are still suffering and dying from this disease. TB is one of the main three irresistible slaughtering sicknesses on the planet: HIV/AIDS executes 1.1 million individuals every year, TB eliminate 1.4 million and malaria slaughters 1 million.[3] Even though tubercle bacilli were identified nearly 130 years ago, a definitive understanding of the pathogenesis of this disease is still deficient. Although it can influence individuals of all ages, people with debilitated insusceptible frameworks e.g., with HIV infection, are at increased risk. Since the system in healthy people walls off the causative bacteria, TB infection in healthy people is usually asymptomatic. This bacterium lives and multiplies within the macrophages, thus avoiding the natural defence system within the patient's serum. Infection with TB may result in two stages: asymptomatic latent tuberculosis infection (LTBI) or tuberculosis disease. If left untreated, the death rate with this disease is over 50%.[1]

GLOBAL SCENARIO OF TB

TB prevalence has never been measured at the national level because it needs a long-term study among large groups of the population at elevated cost as well as demanding logistics. The foremost approach to estimating TB incidence is from regime scrutiny systems

in which case reports are more or less perfect, such that proclamations can be examined a close representative of incidence.[4] This is feasible in condition with intra-continental health-care coverage, and in which operational research has been used to quantify the small fraction of cases that are treated but not notified to surveillance systems.[5]

TB commonness can be directly measured in extensive population-based surveys in countries with a high burden of TB.[6] Ever since 2002, a total of 19 domains have accomplished in measuring the incidences of TB disease through such survey including as many as seven in Africa, along with 14 more that have been planned to be put into action as reported by a report by 2015. Repeat survey conducted about every decade allows trends in disease burden to be evaluated. Countries that have completed repeat surveys in the last decade include Cambodia, China, the Philippines, and Thailand, and repeat surveys are planned in Myanmar and Vietnam.[7] Such surveys have proved to be crucial for designing and familiarizing national TB control program strategies. A large proportion of the global burden of TB as voiced in relation with TB incidence will be rightly measured from population-based surveys shortly, this is as opposed to unrighteous calculated from statistical modelling. The incidence of and mortality from MDR-TB can be calculated from periodic surveys or routine drug-susceptibility testing (DST) if the coverage of patient testing is sufficiently comprehensive (WHO 2013a). The global surveillance of resistance to a minimum of the 2 most vital first-line anti-TB drugs—isoniazid and rifampicin—has been coordinated by the WHO since 1994.[8] Extensively drug-resistant TB (XDR-TB) is defined as MDR-TB plus resistance to the two most effective classes of second-line drugs— the fluoroquinolones and second-line injectable drugs (the aminoglycosides amikacin and kanamycin, and the polypeptide capreomycin) Sources of data available to inform estimates of TB disease burden in the 20 high TB burden countries, 2000–2019[9]

Country	Notification Data	Standards And Benchmark Assessment	National Inventory Study	National Tb Prevalence Surveys	National Drug Resistance Surveyor Surveillance	National Vr Data Or Mortality Surveye
Angola	2000-2019	2016,2019				
Bangladesh	2000-2019	2014,2019		2015	2011,2019	
Brazil	2000-2019	2018		NA	2008	2000-2017
Cambodia	2000-2019	2018		2002,2011	2007,2018	
Central African Rep.	2000-2019	2019			2009	
China	2000-2019		2018	2000,2010	2007,2013	2004-2018
Congo	2000-2019	2019				
DPR Korea	2000-2019	2017		2016	2014	
DR Congo	2000-2019	2017,2019			2017	
Ethiopia	2000-2019	2013,2016		2011	2005,2018	
India	2000-2019	2019	2016	2019-2021	2016	2000-2014
Indonesia	2000-2019	2017,2019	2017	2013-2014	2018	2006-2007,2009-2015
Kenya	2000-2019	2013,2017	2013	2015	2014	
Lesotho	2000-2019	2014,2017		2019	2014	
Liberia	2000-2019	2015,2019				
Mozambique	2000-2019	2013		2017-2019	2007-2021	
Myanmar	2000-2019	2014,2017		2009,2018	2013,2018-2020	
Namibia	2000-2019	2016,2019		2017-2018	2008,2015,2018	
Nigeria	2000-2019	2017,2020		2012	2010	
Papua New Guinea	2000-2019	2017			2014	

THE BURDEN OF TB IN INDIA

India accounts for a few quarters of the worldwide TB burden. In 2018 the estimated TB incidence was 2,690,000. An estimated 9,700 HIV positive people died thanks to TB disease, and an estimated 440,000 HIV negative people died.[10] There are some more TB statistics for India. India is additionally the country with the second-highest number (after South Africa) of estimated HIV associated TB cases.

Estimates of TB Burden (WHO 2018)	Number	Rate per 100,000 Population
Incidence of TB cases (includes HIV + TB)	2.690 million	199
Incidence (HIV+TB only)	92,000	6.6
Incidence (MDR/RR-TB)	130,000	9.6
Mortality (deaths) (excludes HIV+TB)	440,000	32
Mortality (deaths) (HIV+TB only)	9,700	0.72

Table: The TB incidence figure for India is interim pending the results from the national TB prevalence survey planned for 2019/2020.[10]

HIV/TB

HIV and TB can be a lethal combination, every dashing the other's progress, and folks with HIV would die from a TB infection within months. TB is ready to unfold through the body a lot of simply in people living with HIV, that is why TB-HIV is related to extra-pulmonary TB. Active TB accelerates the progress of AIDS infection within the body. The sputum of an HIV-positive person usually contains a lower concentration of TB bacteria, making it harder to detect in a sputum test. Extra-pulmonary TB, which is more common among HIV-positive people than HIV-negative people, cannot be detected through either sputum smear microscopy or chest x-rays. TB medication and antiretroviral therapy (ART) need to be carefully monitored to avoid adverse drug interactions and side effects in patients. Treatment may take longer in people living with HIV, due to the likelihood of extra-pulmonary TB. Even after treatment, they are more vulnerable to getting TB again. Those who have been treated for pulmonary TB remain infectious to others for longer after initiating treatment.[11]

The recommended treatment of TB disease in adults infected with HIV is a 6-month daily regimen consisting of: An intensive phase of isoniazid (INH), a rifamycin (see Drug Interactions below), pyrazinamide (PZA), and ethambutol (EMB) for the first 2 months. Subsequently a continuation phase of INH and a rifamycin for the last 4 months.

Treatment of drug-resistant TB in persons with HIV infection is the same as for patients without HIV; but the, management of HIV-related TB requires expertise in the management of both HIV and TB.

For persons with HIV who are not already on ART, treatment for HIV should be initiated throughout treatment for TB disease, rather than at the end, to improve outcomes among TB patients co-infected with HIV. Anti-retroviral therapy should ideally be initiated within the first 2 weeks of TB treatment for patients with CD4 cell counts <50/mm3 and by 8-12 weeks of TB treatment initiation for patients with CD4 cell counts ≥50/mm3. An important exception is HIV-infected patients with TB meningitis, in whom antiretroviral therapy should not be initiated in the first 8 weeks of anti-tuberculosis therapy.[12]

Estimated epidemiological burden of HIV/TB in 2019 for 20 high TB burden countries, WHO regions and globally[13]

Country	Population	Total Tb Incidence		Hiv-Positive Tb Incidence		Hiv-Negative Tb Mortality		Hiv-Positive Tb Mortality	
		Best Estimate	Uncertainty Interval	Best Estimate	Uncertainty Interval	Best Estimate	Uncertainty Interval	Best Estimate	Uncertainty Interval
Angola	31 800	112	72-160	8.5	5.5-12	17	10-26	2.6	1.7-3.7
Bangladesh	16300	361	262-474	0.70	0.35-1.2	38	24-56	0.15	0.074-0.26
Brazil	211 000	96	82-111	11	9.2-12	4.9	4.7-5.1	1.8	1.4-2.4
Cambodia	16500	47	31-68	1.3	0.81-1.8	2.9	1.8-4.2	0.41	0.26-0.59
Central African Rep.	4750	26	17-37	6.5	4.2-9.3	4.6	2.7-7.0	2.9	1.8-4.2
China	143000	833	717-957	14	12-16	31	28-34	2.2	1.7-2.9
DPR Korea	25700	132	115-150						
DR Congo	86800	278	180-397	30	19-42	43	26-25	9.6	6.2-14
Ethiopia	112000	157	110-211	10	7.1-14	21	14-31	2.8	1.9-3.8
India	137000	2640	1800-3630	71	49-98	436	404-469	9.5	6.0-14
Indonesia	271000	845	770-923	19	8.0-35	92	86-98	4.7	1.9-8.8
Kenya	52600	140	86-208	37	22-54	20	11-30	13	7.8-19
Lesotho	2130	14	8.6-20	8.6	5.3-13	1.2	0.69-1.9	3.6	2.2-5.3
Liberia	4940	15	9.8-22	2.2	1.4-3.1	2.8	1.6-4.2	0.86	0.55-1.2
Mozambique	30400	110	68-162	37	23-55	5.8	3.1-9.3	5.6	3.3-8.6
Myanmar	54000	174	114-245	14	8.9-19	19	12-29	3.1	2.1-4.4
Namibia	2490	12	8.7-16	3.9	2.8-5.2	1.4	0.90-2.0	1.3	0.86-1.7
Nigeria	20100	440	287-625	46	30-66	127	74-195	27	17-40
Papua New Guinea	8780	38	31-46	1.5	0.72-2.4	4.1	2.7-5.8	0.31	0.15-0.54
Philippines	10800	599	336-936	11	4.7-21	27	23-310	8.1	<0.01-4.4

COVID-19 PANDEMIC AND TB

The COVID-19 pandemic impends to reverse recent progress in reducing the worldwide burden of TB disease The global number of TB deaths might increase by around zero.2–0.4 million in 2020 alone if health services are discontinuous to the extent that the number of individuals with TB WHO are detected and treated falls by 25–50% over an amount of three months. In India, Indonesia, the Philippines and African nation, four countries that account for a quarter-mile of worldwide TB cases, there have been giant drops within the reportable range of individuals diagnosed with TB between January and June 2020 Compared with an equivalent 6-month amount in 2019, overall reductions in an Asian country, Indonesia and also the Philippines were within the vary of 25–30%.

In line with WHO steering, actions that countries have reported taking to mitigate impacts on essential TB services embody enlarged use of digital technologies for remote recommendation and support (108 countries together with 21 high TB burden countries) and reducing the requirement for visits to health facilities by giving preference to home-based treatment and providing TB patients with a one-month offer of medicine.

The Stop TB Partnership study carried out in collaboration with Avenir Health, Imperial College (London, United Kingdom of Great Britain and Northern Ireland)and the United States Agency for International Development(USAID) – suggested that a 3-month lockdown combined with a protracted (10-month) restoration of services could cause an additional 1.4 million TB deaths between 2020 and 2025.

There is already evidence from several high TB burden countries of great reductions in the monthly number of people with TB being detected and officially reported in2020, especially in India, Indonesia, the Philippines, Sierra Leone and South Africa

In India, the weekly and a monthly number of TB case notifications fell by more than 50% between the end of March and late April, following the imposition of a national lockdown. Subsequently, there has been some recovery, but as of the end of June, not to pre-March levels. Decreases occurred in both the public and private sector.

WHO guidance and support for the TB response during the COVID-19pandemic

WHO declared COVID-19 a Public Health Emergency of International Concern (PHEIC) in January 2020, the WHO Global TB Programme has monitored the impact of COVID-19 on TB and has provided guidance. This has been done in close collaboration with WHO's regional and country offices, civil society and partners, including the Stop TB Partnership and Global Fund. WHO has also created a compendium of research related to TB and COVID-19.

WHO has provided key advice including the following.

- leverage the expertise and experience of NTPs, especially in rapid testing and contact tracing for the COVID-19 response;
- maximize remote care and support for people with TB by expanding the use of digital technologies;
- minimize the number of visits to health services that are required during treatment, including through the use of WHO-recommended, all-oral TB treatment regimens and community-based care; maintain and scale up TB preventive treatment, including via synergies with contact tracing efforts related to COVID-19;
- provide simultaneous testing for TB and COVID-19 for individuals when indicated, including by leveraging TB laboratory networks and platforms; and
- ensure proactive planning and budgeting for both conditions (including for the catch-up phase), procurement of supplies and risk management.
- limit transmission of TB and COVID-19 in congregate settings and health care facilities by ensuring basic infection prevention and control for health staff and patients, cough etiquette, and patient triage;[13]

DRUG-RESISTANT TB

Two important types of drug-resistant TB have been identified; MDR-TB is a kind of tuberculosis (TB) infection by bacteria that are resistant to treatment with two of the most powerful first-line anti-TB drugs, isoniazid and rifampin and XDR-TB is a guise of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).[14] The causes why multidrug resistance continues to emerge and escalated are mismanagement of TB treatment and person-to-person transmission. Most people with TB are cured by a rigorously following, 6-month drug regimen that is provided to patients with support and supervision.[15] Ill-suited or erroneous use of antimicrobial drugs, or use of ineffective formulations of drugs (such as the use of single drugs, poor-quality medicines or bad storage conditions), and premature treatment interruption can cause drug resistance, which can then be transmitted, especially in crowded settings such as prisons and hospitals.[16] In some countries, it is becoming increasingly arduous to treat MDR-TB. Treatment options are restricted and exorbitant, recommended medicines are not always available, and patients experience many adverse effects from the drugs. In some cases, even more, severe drug-resistant TB may develop. XDR-TB is a form of multidrug-resistant TB with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. XDR TB **so** consequential Because XDR TB is resistant to the most potent TB drugs, the remaining treatment options are less effective, have more side effects, and are more

expensive.[17] XDR TB is of special concern for persons with HIV infection or other conditions that can weaken the immune system.[18] These persons are more anticipate to develop TB disease once they are infected, and they also have a higher risk of death if they develop TB disease. People may get XDR-TB in one amongst two ways. It's going to develop in an exceedingly patient who is receiving treatment for active TB, when anti-TB drugs are misused or mismanaged, and is sometimes an indication of inadequate clinical care or drug management. It can happen when patients aren't properly supported to complete their full course of treatment; when health-care providers prescribe the incorrect treatment, or the incorrect dose, or for too short a period; when the provision of medicine to the clinics dispensing drugs is erratic; or when the drugs are of poor quality.

The second way that folks can develop XDR-TB is by becoming infected from a patient who is already ill with the condition. Patients with TB of the lungs can spread the disease by coughing, sneezing, or just talking. an individual needs only to inhale a tiny low number of those germs to become infected. However, only a small proportion of individuals infected with TB germs develop the disease. someone may be infected by XDR-TB bacteria but not develop the active disease, even as with drug-susceptible TB.

XDR-TB patients are often cured, but with the presently available, the likelihood of success is much smaller than in patients with ordinary TB or perhaps MDR-TB. Cure depends on the extent of the drug resistance, the severity of the disease and whether the patient's immune system is compromised.

Patients infected with HIV may have higher mortality. Early and accurate diagnosis is important so that effective treatment is provided as soon as possible. Effective treatment requires that an honest selection of second-line drugs is out there to clinicians who have special expertise in treating such cases.

MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS

1. Health education and counselling on the disease and treatment adherence should be provided to patients on TB treatment (strong recommendation, moderate certainty within the evidence).
2. A package of treatment adherence interventions could also be offered to patients on TB treatment in conjunction with the choice of an appropriate treatment administration option (conditional recommendation, low certainty in the evidence).
3. One or more of the subsequent treatment adherence interventions (complementary and not mutually exclusive) could also be offered to patients on TB treatment or to health-care providers:

a) tracers and/or digital medication monitor34 (conditional recommendation, very low certainty within the evidence);
b) material support to the patient (conditional recommendation, moderate certainty within the evidence);
c) psychological support to the patient (conditional recommendation, low certainty within the evidence);
d) staff education(conditional recommendation, low certainty within the evidence).

4. The subsequent treatment administration options are also offered to patients on TB treatment:

a) Community- or home-based DOT is suggested over health facility-based DOT or unsupervised treatment (conditional recommendation, moderate certainty within the evidence).
b) DOT administered by trained lay providers or health-care workers is suggested over DOT administered by family members or unsupervised treatment (conditional recommendation, very low certainty in the evidence).
c) Video-observed treatment (VOT) may replace DOT when the video communication technology out there, and it can be appropriately organized and operated by health-care providers and patients (conditional recommendation, very low certainty in within the evidence).
d) Patients with MDR-TB should be treated using mainly ambulatory care instead of models of care based principally on hospitalization (conditional recommendation, very low-quality evidence).
e) A decentralized model of care is suggested over a centralized model for patients on MDR-TB treatment (conditional recommendation, very low certainty within the evidence).[19]

CONCLUSIONS

TB is a leading global communicable disease and demands more attention and resources to combat its spread. The proliferation of MDR-TB and XDR-TB strains greatly exacerbates the potentially devastating consequence epically within the era of COVID -19 to the health of people and populations, as well as to the health thrift, of both developing and developed countries. MDR –TB and XDR-TB is a man-made hindrance and its appearance can be prevented by prompt diagnosis and effective treatment of all TB cases. Adoption of Directly Observed Treatment - Short-course (DOTS) to forestall multi-drug resistant strains and careful introduction of second-line drugs to treat patients with MDR-TB are priorities for the proper control of MDR-TB.

CONFLICT OF INTERESTS

The authors have no conflict of interests in this paper.

REFERENCES

1. Sandhu G. Tuberculosis: Current situation, challenges and overview of its control programs in India [Internet]. Vol. 3, Journal of Global Infectious Diseases. Wolters Kluwer -- Medknow Publications, 2011 [cited 2020 Oct 19]. p. 143–50. Available from: /pmc/articles/PMC3125027/?report=abstract.
2. R.Ananthanaryan CP. Textbook of Microbiology.

Vol. 7, Orient Longman, 2006; 351–2.
3. TB Alliance [Internet]. Available from: https://www.tballiance.org/why-new-tb-drugs/global-pandemic
4. O'Neill K, Takane M, Sheffel A, Abou-Zahr C BT. Monitoring service delivery for universal health coverage: The Service Availability and Readiness Assessment. Bull World Health Organ, 2013; (91): 923–931.
5. Van Hest N, Story A, Grant AD, Antoine D, Crofts JP WJ. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999–2002. Epidemiol Infect, 2008; 136: 1606–1616.
6. Glaziou P, van der Werf MJ, Onozaki I, Dye C, Borgdorff MW, Chiang CY, Cobelens F, Enarson DA, Gopi PG, Holtz TH et al. Tuberculosis prevalence surveys: Rationale and cost. Int J Tuberc Lung Dis, 12: 1003–8.
7. WHO. 2013a. Global TB report 2013 WHO, Geneva.
8. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Heal Organ Union against Tuberc Lung.
9. Global TB Report 2019", WHO, 2019.
10. TB in India - Elimination, Private Care & NSP - TBFacts [Internet]. [cited 2020 Nov 4]. Available from: https://tbfacts.org/tb-india/
11. TB and HIV - TB Alert [Internet]. [cited 2020 Nov 9]. Available from: https://www.tbalert.org/about-tb/global-tb-challenges/tb-hiv/
12. Treatment of Persons Living with HIV | Treatment | TB | CDC [Internet]. Available from: https://www.cdc.gov/tb/topic/treatment/tbhiv.htm
13. GLOBAL TUBERCULOSIS REPORT 2020 [Internet]. 2020. 15 p. Available from http://www.ghbook.ir/index.php?name=&option=com_dbook&task=readonline&book_id=13629&page=108&chkhashk=03C706812F&Itemid=218&lang=fa&tmpl=component
14. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and ExtensivelyDrug-Resistant Tuberculosis, 2015; 1–20.
15. Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). 2018; Available from: https://www.who.int/news-room/q-a-detail/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)
16. Tb XDR. XDR TB. Cent Dis contol Prev [Internet]. :1–3. Available from: https://www.cdc.gov/tb/publications/factsheets/drtb/xdrtb.htm.
17. infected with hiv. Available from: https://context.reverso.net/translation/english-spanish/infected+with+hiv
18. The B, Close B. Frequently Asked Questions : XDR- - - TB.
19. WHO. Consolidated Guidelines on Tuberculosis Treatment. Who, 2016; 99.